Background & Aims: This observational retrospective study aimed at evaluating the effects of one-year administration of homotaurine (tramiprosate) in a sample patients presenting with symptoms of mild cognitive impairment. Methods: Patient’s demographic data and medical history are reported. Each patient performed brain imaging and neuropsychological assessment to reach the diagnosis. Each patient assumed 100 mg total dose of homotaurine/day. The evolution of the cognitive decline over time was evaluated my means of the Mini Mental State Examination (MMSE). Results: 245 patients from 28 different centres in Italy were recruited. Significant improvements from baseline expressed as mean MMSE total score were observed in patients with aMCI at months 8 and 12 (p < 0.0001), and in those with mMCI at month 4 (p < 0.05). Conclusions: Administration of homotaurine revealed beneficial effects in our sample population of MCI patients. Our results indicate clearly that homotaurine may well be considered as a potential symptomatic treatment for cognitive symptoms. Further research is however needed to clarify whether this compound could influence the progression of cognitive decline.
|Number of pages||6|
|Journal||Journal of Gerontology and Geriatrics|
|Publication status||Published - Jan 1 2018|
- Alzheimer’s disease
- Mild cognitive impairment
ASJC Scopus subject areas
- Geriatrics and Gerontology